What question did this study set out to answer?

This study aimed to evaluate the associations between proton pump inhibitors and survival outcomes in advanced NSCLC patients undergoing immunotherapy.

July 23, 2026MedicinaOpen Access

Proton Pump Inhibitor Use and Survival Outcomes in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Immunotherapy: A Real-World Study

View Full Paper

Ask AI

Bookmark

Authors

SKSalih KaratlıMemorial Ankara Hospital SKSeher KayaMemorial Ankara Hospital SÇSelahattin ÇelikMinistry of Health

Discussion

Member takes

Implication

Retrospective cohort study examines PPI use's impact on survival in advanced NSCLC patients receiving nivolumab, suggesting caution in PPI prescriptions.

Key Points

This study aimed to evaluate the associations between proton pump inhibitors and survival outcomes in advanced NSCLC patients undergoing immunotherapy.
Performed a retrospective cohort study of 179 advanced NSCLC patients treated with nivolumab.
Assessed PPI, metformin, statin, and NSAID use within a ±30-day window around nivolumab initiation.
Analyzed progression-free survival and overall survival using Kaplan-Meier and Cox regression models.
PPI use was associated with worse progression-free survival (PFS HR = 2.22, p < 0.001).
Median PFS was 5 months for PPI users versus 9 months for non-users (p < 0.001).
PPI use also indicated worse overall survival (OS HR = 2.01, p = 0.002) with median OS at 9 months for users versus 14 months for non-users (p = 0.036).

Cite This Study

Karatlı et al. (2026) studied this question.

synapsesocial.com/papers/6a61b004faa9903c5116abbb https://doi.org/10.3390/medicina62071413

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study examines PPI use's impact on survival in advanced NSCLC patients receiving nivolumab, suggesting caution in PPI prescriptions.

Proton Pump Inhibitor Use and Survival Outcomes in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Immunotherapy: A Real-World Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Proton Pump Inhibitor Use and Survival Outcomes in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Immunotherapy: A Real-World Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider